Vigilant Biosciences
  • About
    • Leadership
    • Boards
    • Investors
    • Careers
    • Contact Us
  • Oral Cancer
    • Why We Fight
  • Technology
    • Non-U.S. Markets
    • R&D
  • Resources
    • Publications
    • References
  • News
    • Press Releases
    • Media Coverage
    • Events
    • Press Kit
  • Partner with Us
×
  • AboutExpand
    • LeadershipExpand
    • BoardsExpand
    • InvestorsExpand
    • CareersExpand
    • Contact UsExpand
  • Oral CancerExpand
    • Why We FightExpand
  • TechnologyExpand
    • Non-U.S. MarketsExpand
    • R&DExpand
  • ResourcesExpand
    • PublicationsExpand
    • ReferencesExpand
  • NewsExpand
    • Press ReleasesExpand
    • Media CoverageExpand
    • EventsExpand
    • Press KitExpand
  • Partner with UsExpand

Press Releases

August 7, 2018

Vigilant Biosciences Names William Brodie as Chief Executive Officer

FORT LAUDERDALE, Fla., Aug. 7, 2018 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of oral and throat cancer, today…

Read

June 21, 2017

Fort Lauderdale, Fla. and WASHINGTON and PARIS

Vigilant Biosciences Announces Further Clinical Data in Support of its OncAlert™ Oral Cancer Product Line at IFOS ENT World Congress 2017 Symposium and at Annual MASCC Meeting

Company to exhibit as Bronze Sponsor of IFOS ENT World Congress and present interim analysis of European clinical studies in support of its OncAlert Oral Cancer product line Vigilant Biosciences,…

Read

June 13, 2017

Fort Lauderdale, FLA.

Vigilant Biosciences Announces Grant Award from National Institutes of Health

Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the that it has received an award as…

Read

May 10, 2017

Vigilant Biosciences Announces Commencement of FDA Studies for OncAlert™ Cancer Test

Company begins drive toward FDA clearance of first and only test to detect a tumor-initiating stem cell-associated biomarker for oral and oropharyngeal cancer Vigilant Biosciences, Inc., a leading innovator and…

Read

March 30, 2017

Fort Lauderdale, Fla.

Oral Cancer Awareness Survey Reveals 81 Percent of U.S. Adults Want to Be Screened for Oral Cancer During Routine Dental Check-ups; Only 29 Percent Actually Are

Survey conducted by Vigilant Biosciences, Head and Neck Cancer Alliance, Oral Cancer Foundation and Support for People with Oral and Head and Neck Cancer reveals low awareness, misconceptions and desire…

Read
Pages 1 2 3 … 9 »
  • Privacy Policy
  • Terms of Use

©2019 by or under license to Vigilant Biosciences, Inc. All Rights Reserved.